Why the CSL (ASX:CSL) share price is seesawing over the past month

The CSL Limited (ASX: CSL) share price has been wobbling over the past few months. We take a closer look at the company, and its most recent update.

| More on:
volatile asx share price represented by two investors on a seesaw

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been wobbling in recent times following the company's ongoing plasma collection issues. Investors hit the sell button in February and March after digesting CSL's half-year results announcement and experiencing a broader market slump thereafter.

While the global biotech's shares have stabilised for now, the company is still facing headwinds.

At the time of writing, CSL shares are swapping hands for $271.38, up 0.16%.

What's going on with CSL?

CSL has been in the spotlight receiving heavy media attention about its plasma stockpile, and AstraZeneca plc (NASDAQ: AZNCOVID-19 vaccine update.

First and foremost, CSL's plasma collections have taken a hit over the past 14 months, adversely impacted by the pandemic. Fewer people are donating blood to the company's collection centres as countries go into lockdown following new COVID-19 waves.

Plasma, derived from blood, is a key ingredient in the production of life-saving therapies. CSL's most recent update in March advised that December 2020 plasma volumes stood at 80% of December 2019 levels.

The company has been busy targeting marketing initiatives to increase collections, along with opening new centres.

Only time will tell if the biotech leader can build back up its plasma stockpile in the short-term.

Moving on, CSL provided an update last Saturday on its COVID-19 vaccine manufacturing numbers. It said that over 1 million doses are being produced each week and is scheduled for release in mid-May. This is provided that the required quality checks are approved.

CSL noted that there is about a 4-week quality control and approval process in which each batch is stringently tested. This is undertaken by AstraZeneca, the Australian Therapeutic Goods Administration (TGA) and CSL.

To date, over 3.7 million doses of locally made AstraZeneca COVID-19 vaccines have been released. However, current COVID-19 vaccinations administered across the country stands at around 2.3 million. The remaining 1.4 million vials are either sitting in cold storage or facing transportation delays to clinics and pharmacies.

CSL share price summary

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, down 9%. The company's shares are currently sitting just below the mid-range of $242.00 to $320.42 achieved over the year's timeframe.

On valuation grounds, CSL is the third largest company on the ASX with a market capitalisation of roughly $123 billion.

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »